Prof. Dr. Eveline Lescrinier

contact

• see whoiswho

research projects

• Synthesis and characterisation of backbone modified mRNA [more...]
• Optimization of self-amplifying RNA and mRNA production and formulation through advanced microfluidics. [more...]
• MORPHO-ViBe. Developping a new probe harboring vibrational Stark effect spectroscopic sensitivity and targeting the catalytic pocket of the ribosome [more...]
• Exploring Novel Synergies Between Antiviral Nucleotides and Small Molecule Immunomodulators for Hepatitis B virus (HBV) Treatment [more...]
• Development of alkyl-PMO based antibiotics [more...]
• Developing XNA aptamer selection tools for the advancement of aptamer diagnostic and therapeutic applications [more...]
• Development of broad spectrum antibiotics with a new mode of action through establishing new tools for optimal sequence selection in vitro and in silico design of antisense oligonucleotides. [more...]
• Stereocontrolled synthesis and characterization of novel sugar-phosphate modified nucleotides [more...]
• Artificial genetic systems with stereocontrolled sugar-phosphate backbone: towards advanced therapy and synthetic biology. [more...]
• Molecular modeling tools to improve and expand computational research on synthetic nucleic acids [more...]

recent publications

• Chaillou, S., Bernardes Pinheiro, V. (sup.), Herdewyn, P. (cosup.), Lescrinier, E. (cosup.) (2026). Defining, analyzing, and engineering functional nucleic acid systems.
• El Arnouki Belhaji, F., De Ruysscher, D., Vanreppelen, G., Huybrechts, L-L., Alanjary, M.M., Zdouc, M.M., de los Santos, E.L C., Demaerel, J., Vaneeckhaute, E., Van Goethem, O., Gerstmans, H., Breynaert, E., Van Dijck, P., Medema, M.H., Weir, A.N M., Lescrinier, E., Masschelein, J. (corresp. author) (2026). Charting the Biosynthetic Landscape of Hybrid Polyketide-Nonribosomal Peptide-Specialized Lipids. JACS Au, 6 (6), 3363-3375. doi: 10.1021/jacsau.6c00386
• Chaillou, S. (joint first author), Thonon, S. (joint first author), Reynders, S., Lescrinier, E., Pinheiro, V.B. (corresp. author) (2026). Are we there yet with XNA aptamers? RSC ADVANCES, 16 (24), 22227-22246. doi: 10.1039/d5ra05395a
• Derden, M., Lescrinier, E. (sup.), Groaz, E. (cosup.) (2026). Stereocontrolled synthesis and characterization of novel sugar-phosphate modified nucleotides.
• Lelong, J., Lescrinier, E. (contr.) (2025). China maakt als tweede grootste medicijnenproducent ook alsmaar meer innovatieve medicatie. De Morgen.
• Lescrinier, E. (contr.) (2025). Opmars van chinese bedrijven zet belgische farmasector onder druk. Het Laatste Nieuws.
• Tu, L., Horak, J. (corresp. author), Krentz, D., Zwicklbauer, K., Hartmann, K., Lescrinier, E., Alberer, M., von Both, U., Koletzko, B. (corresp. author) (2025). Structure elucidation and quantification of the active pharmaceutical ingredient in a non-approved drug and in cat serum using QTRAP-MS/MS and ZenoTOF-MS/MS. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 265, Art.No. ARTN 116995. doi: 10.1016/j.jpba.2025.116995
• Bulai, R-G., Van Eynde, W., Heylen, S., Cremonini, M., Van Olmen, F., Wicik, R., Lescrinier, E., Rozenski, J., Voet, A., Masschelein, J. (corresp. author), Verwilst, P. (corresp. author) (2025). Investigating the structure-activity-relationship of diaryl ether-based paFabV inhibitors: A path to novel antibacterials. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 296, Art.No. ARTN 117782. doi: 10.1016/j.ejmech.2025.117782
• Goffin, E., Torfs, L., Tsingis, F., Svestka, D., Erven, K., Uyttersprot, K., Heens, C., Wilms, S., Rozenski, J., Lescrinier, E., Pannecouque, C., Verwilst, P. (corresp. author) (2025). Discovery and SAR exploration of novel nanomolar 3,4-dihydroquinazolin-2(1H)-one non-nucleoside reverse transcriptase inhibitors. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 296, Art.No. ARTN 117818. doi: 10.1016/j.ejmech.2025.117818
• Derden, M., Reynders, S., Rihon, J., Li, X., Coosemans, F., Rozenski, J., Herdewijn, P., Groaz, E. (corresp. author), Lescrinier, E. (corresp. author) (2025). Tuning i-motif folding and stability with acyclic phosphonate-linked (ZNA) cytidine residues. RSC ADVANCES, 15 (44), 37099-37108. doi: 10.1039/d5ra05934h

For a complete list of publications, see lirias database or PubMed.